Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Core Viewpoint - Ernexa Therapeutics Inc. has announced a public offering of 21 million shares of common stock at a price of $0.50 per share, aiming to raise approximately $10.5 million before expenses [1][4]. Group 1: Offering Details - The offering includes warrants to purchase up to 21 million shares at an exercise price of $0.68, which will expire either five years after issuance or 180 days after the release of clinical trial data for ERNA-101 [2]. - The closing of the offering is expected around February 10, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance development programs, support working capital, and cover general corporate purposes [3]. Group 3: Financial Projections - The total gross proceeds from the offering are estimated at approximately $10.5 million, with potential additional proceeds of about $14.3 million from the exercise of the warrants if fully exercised [4]. Group 4: Company Overview - Ernexa Therapeutics focuses on developing innovative cell therapies for advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create allogeneic synthetic mesenchymal stem cells (iMSCs) [7]. - The lead product, ERNA-101, is designed to enhance the immune system's ability to target cancer cells, with an initial focus on ovarian cancer treatment [8].